{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:03:37Z","timestamp":1781625817433,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To analyze the incidence, and clinical characteristics of intraocular inflammation (IOI) associated with faricimab in a tertiary center in Austria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis of IOI cases following intravitreal faricimab injections in the Kepler University Hospital Linz, Austria. Clinical data was analyzed from January 2023, until March 10th 2025. Clinical and optical coherence tomography (OCT) findings including vitreous changes via mean vitreous grey value (MVGV) were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 7333 intravitreal injections of faricimab for a total of 1137 patients were applied during the observation period. We identified 11 eyes with an IOI after faricimab injection with a mean follow up of 22.5 days (range 3\u201342 days) which corresponds to an incidence of IOI of 0.15% per injection. Quantitative OCT analysis showed a significant rise in mean vitreous gray value during IOI (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), which returned to baseline after treatment (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.63). A significant, fully reversible increase in vitreous haze during IOI episodes was shown. Clinical findings included both anterior and posterior segment inflammation in the absence of pain or occlusive vasculitis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results suggest a low incidence of IOI after faricimab injections, comparable to registration trials. MVGV analysis via OCT proved to be sensitive and reproducible. All cases resolved with topical treatment. Intravitreal therapy with faricimab has shown to have a low risk of adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00754-6","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T14:51:10Z","timestamp":1764687070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quantitative analysis of vitreous changes in intraocular inflammation following faricimab treatment in a real world setting"],"prefix":"10.1186","volume":"11","author":[{"given":"Clemens","family":"Th\u00fcrridl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"D\u00f6rfler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rothb\u00e4cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Eidherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidar","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Huemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"754_CR1","doi-asserted-by":"publisher","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet [Internet]. 2022;399(10326):729\u201340. Available from: https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"754_CR2","doi-asserted-by":"publisher","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet [Internet]. 2022;399(10326):741\u201355. Available from: https:\/\/doi.org\/10.1016\/S0140-6736(22)00018-6","DOI":"10.1016\/S0140-6736(22)00018-6"},{"key":"754_CR3","doi-asserted-by":"publisher","unstructured":"Danzig CJ, Dinah C, Ghanchi F, Hattenbach LO, Khanani AM, Lai TYY et al. Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials. Ophthalmol Retina [Internet]. 2025; Available from: https:\/\/doi.org\/10.1016\/j.oret.2025.03.005","DOI":"10.1016\/j.oret.2025.03.005"},{"key":"754_CR4","doi-asserted-by":"publisher","unstructured":"Bourdin A, Cohen SY, Nghiem-Buffet S, Smadja J, Paques M, Fajnkuchen F et al. Vitritis following intravitreal faricimab: a retrospective monocentric analysis. Graefes Arch Clin Exp Ophthalmol [Internet]. 2025;263(4):965\u201372. Available from: https:\/\/doi.org\/10.1007\/s00417-025-06736-6","DOI":"10.1007\/s00417-025-06736-6"},{"key":"754_CR5","doi-asserted-by":"publisher","unstructured":"Montesel A, Sen S, Preston E, Patel PJ, Huemer J, Hamilton RD et al. INTRAOCULAR INFLAMMATION ASSOCIATED WITH FARICIMAB THERAPY: One-Year Real-World Outcomes. Retina [Internet]. 2025;45(5):827\u201332. Available from: https:\/\/doi.org\/10.1097\/IAE.0000000000004394","DOI":"10.1097\/IAE.0000000000004394"},{"key":"754_CR6","doi-asserted-by":"publisher","unstructured":"Keane PA, Karampelas M, Sim DA, Sadda SR, Tufail A, Sen HN et al. Objective measurement of vitreous inflammation using optical coherence tomography. Ophthalmology [Internet]. 2014;121(9):1706\u201314. Available from: https:\/\/doi.org\/10.1016\/j.ophtha.2014.03.006","DOI":"10.1016\/j.ophtha.2014.03.006"},{"key":"754_CR7","doi-asserted-by":"publisher","unstructured":"Zicarelli F, Ometto G, Montesano G, Motta S, De Simone L, Cimino L et al. Objective Quantification of Posterior Segment Inflammation: Measuring Vitreous Cells and Haze Using Optical Coherence Tomography. Am J Ophthalmol [Internet]. 2023;245:134\u201344. Available from: https:\/\/doi.org\/10.1016\/j.ajo.2022.08.025","DOI":"10.1016\/j.ajo.2022.08.025"},{"key":"754_CR8","doi-asserted-by":"publisher","unstructured":"Rahimi M, Khameneh EA, Riazi-Esfahani H, Mahmoudi T, Khalili Pour E, Kafieh R. Application of ImageJ in Optical Coherence Tomography Angiography (OCT-A): A Literature Review. J Ophthalmol [Internet]. 2023;2023:9479183. Available from: https:\/\/doi.org\/10.1155\/2023\/9479183","DOI":"10.1155\/2023\/9479183"},{"key":"754_CR9","doi-asserted-by":"publisher","unstructured":"Montesano G, Way CM, Ometto G, Ibrahim H, Jones PR, Carmichael R et al. Optimizing OCT acquisition parameters for assessments of vitreous haze for application in uveitis. Sci Rep [Internet]. 2018;8(1):1648. Available from: https:\/\/doi.org\/10.1038\/s41598-018-20092-y","DOI":"10.1038\/s41598-018-20092-y"},{"key":"754_CR10","doi-asserted-by":"publisher","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol [Internet]. 2005;140(3):509\u201316. Available from: https:\/\/doi.org\/10.1016\/j.ajo.2005.03.057","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"754_CR11","doi-asserted-by":"publisher","unstructured":"Liu X, Kale AU, Ometto G, Montesano G, Sitch AJ, Capewell N et al. OCT Assisted Quantification of Vitreous Inflammation in Uveitis. Transl Vis Sci Technol [Internet]. 2022;11(1):3. Available from: https:\/\/doi.org\/10.1167\/tvst.11.1.3","DOI":"10.1167\/tvst.11.1.3"},{"key":"754_CR12","doi-asserted-by":"publisher","unstructured":"Zarranz-Ventura J, Keane PA, Sim DA, Llorens V, Tufail A, Sadda SR et al. Evaluation of Objective Vitritis Grading Method Using Optical Coherence Tomography: Influence of Phakic Status and Previous Vitrectomy. Am J Ophthalmol [Internet]. 2016;161:172\u201380.e1\u20134. Available from: https:\/\/doi.org\/10.1016\/j.ajo.2015.10.009","DOI":"10.1016\/j.ajo.2015.10.009"},{"key":"754_CR13","doi-asserted-by":"publisher","unstructured":"Sreekantam S, Macdonald T, Keane PA, Sim DA, Murray PI, Denniston AK. Quantitative analysis of vitreous inflammation using optical coherence tomography in patients receiving sub-Tenon\u2019s triamcinolone acetonide for uveitic cystoid macular oedema. Br J Ophthalmol [Internet]. 2017;101(2):175\u20139. Available from: https:\/\/doi.org\/10.1136\/bjophthalmol-2015-308008","DOI":"10.1136\/bjophthalmol-2015-308008"},{"key":"754_CR14","doi-asserted-by":"publisher","unstructured":"Keane PA, Balaskas K, Sim DA, Aman K, Denniston AK, Aslam T et al. Automated Analysis of Vitreous Inflammation Using Spectral-Domain Optical Coherence Tomography. Transl Vis Sci Technol [Internet]. 2015;4(5):4. Available from: https:\/\/doi.org\/10.1167\/tvst.4.5.4","DOI":"10.1167\/tvst.4.5.4"},{"key":"754_CR15","doi-asserted-by":"publisher","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study \u2013\u20096 month results. Eye (Lond) [Internet]. 2023;37(17):3574\u201381. Available from: https:\/\/doi.org\/10.1038\/s41433-023-02553-5","DOI":"10.1038\/s41433-023-02553-5"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00754-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00754-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00754-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:54:19Z","timestamp":1781621659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-025-00754-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00754-6","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional ethics review board of the Johannes Kepler University (EK Nr: 1131\/2025) and adhered to the principles of the Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"After completing the writing and editing of the manuscript, the authors used ChatGPT exclusively for the final revision and minor adjustments. Following the use of this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies in the writing process"}},{"value":"JH speaker fees, travel support: Roche, Bayer, advisory boards: Roche. MB consultancy: Roche. The other authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}